From somatostatin to octreotide LAR: evolution of a somatostatin analogue
Authors:
- 21 October 2009
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 25 (12) , 2989-2999
Abstract
Acromegaly is characterized by overproduction of growth hormone (GH) by the pituitary gland. GH stimulates the synthesis of insulin-like growth factor-I (IGF-I), and the somatic growth and metaboli...Keywords
This publication has 86 references indexed in Scilit:
- Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open‐label, multicentre studyClinical Endocrinology, 2009
- Consensus statement: medical management of acromegalyEuropean Journal of Endocrinology, 2005
- The Diagnosis and Medical Management of Advanced Neuroendocrine TumorsEndocrine Reviews, 2004
- Octreotide Long-Acting Release (LAR)Drugs, 2003
- Pharmacokinetics, Pharmacodynamics, and Safety of Microencapsulated Octreotide Acetate in Healthy SubjectsThe Journal of Clinical Pharmacology, 2000
- Octreotide Long-Acting Release (LAR)Drugs, 1997
- Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferonActa Oncologica, 1993
- AcromegalyNew England Journal of Medicine, 1990
- Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowelDigestive Diseases and Sciences, 1987
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982